A phase II trial of Paclitaxel in the treatment of recurrent or metastatic soft tissue sarcomas or bone sarcomas

Journal of Experimental Therapeutics and Oncology

Volumn 1, Issue 3, 1996, Pages 186-190

  Gian, V G ^a   Johnson, T J ^b   Marsh, R D W ^a   Schuhmacher, C ^a   Lynch, J W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Lackland Air Force Base ^*  (United States)

Author keywords

Paclitaxel; Sarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL;

ADULT; AGED; ARTICLE; BONE TUMOR; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RECURRENT DISEASE; SARCOMA; SOFT TISSUE TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BONE NEOPLASMS; CLINICAL TRIALS, PHASE II; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; RECURRENCE; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 0030132062     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Cancer Statistics 1995. CA-A Cancer Journal for Clinicians 45: 12-13, 1995.
2. Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 5: 840-850, 1987.
3. Schoenfeld D, Rosenbaum C, Horton J, et al. A comparison of adriamycin versus vincristine and adriamycin and cyclophosphamide for advanced sarcoma. Cancer 50: 2757-2762, 1982.
4. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11: 1269-1275, 1993.
5. Bramwell VH, Mouridsen HT, Santoro A, et al. Cyclophosphamide versus ifosphamide: a randomized phase II trial in adult soft-tissue sarcomas. Cancer Chem Pharm 31(S2): S180-S184, 1993.
6. Antman KH, Ryan L, Elias A, et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 7: 126-131, 1989.
7. Lerner H, Amato D, Stevens C, et al. Leiomyosarcoma: The Eastern Cooperative Oncology Group experience with 222 patients. Proc Am Assn Cancer Res 24: 142 (Abs C-561), 2983.
8. Gottlieb JA, Benjamin RS, Baker LH, et al. The role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep 60: 199-203, 1976.
9. Schutte J, Mouridsen HY, Steward W, et al. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma. Cancer Chem Pharm 31(S2): S204-S209, 1993.
10. Antman K, Crowley J, Balcerzak SP, et al. An intergroup Phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 7: 1276-1285, 1993.
11. Meyers P, Heller G, Healy JH, et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 11: 449-453, 1993.
12. Rowinsky EK, Cazenave LA, Donhower RC. Taxol: A novel investigational antimicrotubule agent. J Nat Cancer Inst 82: 1247-1259, 1990.
13. Caldas C, McGuire WP. Paclitaxel (Taxol) therapy in ovarian cancer. Semin in Oncol 20(S3): 50-55, 1993.
14. Forastiere AA. Use of Paclitaxel (Taxol) in squamous cell carcinoma of the head and neck. Semin in Oncol 20(S3): 56-60, 1993.
15. Kirschling RJ, Jung SH, Jett JR. A phase II trial of taxol and G-CSF in previously untreated patients with extensive stage small cell lung cancer. Proc Am Soc Clin Oncol 13: 326, (Abs 1076), 1994.
16. Ettinger DS, Finkelstein DM, Sarma R, et al. Phase II study of taxol in patients with extensive stage small cell lung cancer. Proc Am Soc Clin Oncol 12: 329, (Abs 1094), 1993.
17. Chang A, Kim K, Glick J, et al. Phase II study of taxol in patients with stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group (ECOG) results. Proc Am Soc Clin Oncol 11: 293, (Abs 981), 1992.
18. Murphy WK, Winn RJ, Fossella FV, et al. A phase II study of taxol (NSC 125973) in patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 11: 294, (Abs 985), 1992.
19. Seidman A, Crown J, Reichman B, et al. Lack of clinical cross-resistance of taxol with anthracycline in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 12: 63, (Abs 53), 1993.
20. Gianni L, Capri G, Munzone E, et al. Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines. Seminars in Oncol 21: 29-33, 1994.
21. Thigpen T, Blessing J, Ball H, et al. Phase II trial of taxol as second-line therapy for ovarian carcinoma: A gynecologic oncology group study. Proc Am Soc Clin Oncol 9: 156, (Abs 604), 1990.
22. Balcerzak SP, Benedetti J, Weiss GR, et al. A Phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. Cancer 76(11): 2248-2252, 1995.
23. Simon R. How large should a phase II trial of a new drug be? Cancer Treatment Rep 71: 1079-1085, 1987.
24. van Hoesel O, Verweij J, Clavel M, et al. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. Proc Am Soc Clin Oncol 13: 480, (Abs 1675), 1994.
25. Casper E, Chrisman K, Schwartz G, et al. Edatrexate in patients with soft tissue sarcoma. Cancer 72: 766-770, 1993.
26. Zalupski M, Metch B, Balcerzak S, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft tissue sarcoma: A Southwestern Oncology Group study. J Nat Cancer Inst 83: 926-932, 1991.
27. Loehrer P, Sledge G, Nicasse C, et al. Ifosfamide plus doxorubicin in metastatic adult sarcomas: A multi-institutional phase II trial. J Clin Oncol 7: 1655-1659, 1989.